Bartosz Grzywacz

2.0k total citations
31 papers, 1.2k citations indexed

About

Bartosz Grzywacz is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Bartosz Grzywacz has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 12 papers in Oncology and 7 papers in Hematology. Recurrent topics in Bartosz Grzywacz's work include Immune Cell Function and Interaction (21 papers), T-cell and B-cell Immunology (11 papers) and CAR-T cell therapy research (9 papers). Bartosz Grzywacz is often cited by papers focused on Immune Cell Function and Interaction (21 papers), T-cell and B-cell Immunology (11 papers) and CAR-T cell therapy research (9 papers). Bartosz Grzywacz collaborates with scholars based in United States, Canada and Poland. Bartosz Grzywacz's co-authors include Jeffrey S. Miller, Michael R. Verneris, Bruce R. Blazar, Frank Cichocki, Dan S. Kaufman, Petter Woll, Rebecca Marcus, David A. Knorr, Xinghui Tian and Veronika Bachanová and has published in prestigious journals such as Blood, The Journal of Immunology and Clinical Cancer Research.

In The Last Decade

Bartosz Grzywacz

30 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bartosz Grzywacz United States 14 960 597 266 204 95 31 1.2k
Matthias Zeis Germany 16 634 0.7× 314 0.5× 368 1.4× 229 1.1× 104 1.1× 42 931
Jessica Sachs United States 9 497 0.5× 442 0.7× 206 0.8× 112 0.5× 90 0.9× 23 790
Harumi Kakuda Japan 12 586 0.6× 474 0.8× 398 1.5× 211 1.0× 36 0.4× 28 947
Susann Szmania United States 17 994 1.0× 850 1.4× 590 2.2× 394 1.9× 99 1.0× 40 1.5k
Srinivas S. Somanchi United States 15 1.1k 1.2× 880 1.5× 195 0.7× 224 1.1× 25 0.3× 30 1.3k
Dina Stroopinsky United States 14 315 0.3× 295 0.5× 193 0.7× 392 1.9× 107 1.1× 46 835
Felix S. Lichtenegger Germany 18 698 0.7× 684 1.1× 440 1.7× 428 2.1× 112 1.2× 35 1.3k
Mobin Karimi United States 11 524 0.5× 414 0.7× 198 0.7× 291 1.4× 25 0.3× 32 927
Britt E. Anderson United States 14 1.2k 1.3× 397 0.7× 1.1k 4.0× 154 0.8× 170 1.8× 19 1.6k
May Daher United States 16 629 0.7× 631 1.1× 126 0.5× 275 1.3× 37 0.4× 38 1.0k

Countries citing papers authored by Bartosz Grzywacz

Since Specialization
Citations

This map shows the geographic impact of Bartosz Grzywacz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bartosz Grzywacz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bartosz Grzywacz more than expected).

Fields of papers citing papers by Bartosz Grzywacz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bartosz Grzywacz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bartosz Grzywacz. The network helps show where Bartosz Grzywacz may publish in the future.

Co-authorship network of co-authors of Bartosz Grzywacz

This figure shows the co-authorship network connecting the top 25 collaborators of Bartosz Grzywacz. A scholar is included among the top collaborators of Bartosz Grzywacz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bartosz Grzywacz. Bartosz Grzywacz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Felices, Martin, Laura E. Bendzick, Behiye Kodal, et al.. (2023). Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer. Cancer Immunology Research. 11(5). 674–686. 8 indexed citations
2.
Bachanová, Veronika, J. Žák, Qing Cao, et al.. (2023). Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI). Hematological Oncology. 41(S2). 582–582. 3 indexed citations
3.
Tracy, Sean, et al.. (2022). Proteomic and Transcriptomic Profiling Reveals Insights into Mechanisms of Leukemic Immune Escape. Blood. 140(Supplement 1). 6341–6342. 2 indexed citations
4.
5.
Grzywacz, Bartosz, et al.. (2021). Indolent B-Lineage Precursor Populations Identified by Flow Cytometry and Immunohistochemistry in Benign Lymph Nodes. American Journal of Clinical Pathology. 157(2). 202–211. 3 indexed citations
6.
7.
Weinberg, Olga K., Karen M. Chisholm, Chi Young Ok, et al.. (2021). Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology. 34(7). 1358–1366. 11 indexed citations
8.
Sarhan, Dhifaf, Michael R. Verneris, Bartosz Grzywacz, et al.. (2020). Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. JCI Insight. 5(5). 40 indexed citations
9.
Yohe, Sophia, et al.. (2019). CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up. American Journal of Clinical Pathology. 152(4). 471–478. 6 indexed citations
10.
Erbe, Amy K., Wei Wang, Lakeesha Carmichael, et al.. (2019). Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. Journal for ImmunoTherapy of Cancer. 7(1). 70–70. 14 indexed citations
11.
Cichocki, Frank, Bartosz Grzywacz, & Jeffrey S. Miller. (2019). Human NK Cell Development: One Road or Many?. Frontiers in Immunology. 10. 2078–2078. 106 indexed citations
12.
13.
Bachanová, Veronika, Arthur E. Frankel, Qing Cao, et al.. (2015). Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies. Clinical Cancer Research. 21(6). 1267–1272. 58 indexed citations
14.
Ondrejka, Sarah L., Bartosz Grzywacz, Juraj Bodo, et al.. (2015). Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features. The American Journal of Surgical Pathology. 40(3). 335–341. 50 indexed citations
15.
Alderson, Kory L., Amy K. Erbe, Kimberly A. McDowell, et al.. (2012). Increasing the Clinical Efficacy of NK and Antibody-Mediated Cancer Immunotherapy: Potential Predictors of Successful Clinical Outcome Based on Observations in High-Risk Neuroblastoma. Frontiers in Pharmacology. 3. 91–91. 29 indexed citations
16.
Grzywacz, Bartosz, et al.. (2010). Natural killer–cell differentiation by myeloid progenitors. Blood. 117(13). 3548–3558. 104 indexed citations
17.
Woll, Petter, Bartosz Grzywacz, Xinghui Tian, et al.. (2009). Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood. 113(24). 6094–6101. 215 indexed citations
18.
Grzywacz, Bartosz, Jeffrey S. Miller, & Michael R. Verneris. (2008). Use of natural killer cells as immunotherapy for leukaemia. Best Practice & Research Clinical Haematology. 21(3). 467–483. 32 indexed citations
19.
Grzywacz, Bartosz, Dorota Dłubek, & Andrzej Lange. (2002). NK cells become Ki-67+ in MLC and expand depending on the lack of ligand for KIR on stimulator cells in IL-2 supplemented MLC. Human Immunology. 63(8). 638–646. 5 indexed citations
20.
Giedrys‐Kalemba, Stefania, et al.. (2000). Influence of protective genes in the HLA system on renal graft survival. Transplantation Proceedings. 32(6). 1337–1338. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthias Zeis Breakdown of academic impact, for papers by Jessica Sachs Breakdown of academic impact, for papers by Harumi Kakuda Breakdown of academic impact, for papers by Susann Szmania Breakdown of academic impact, for papers by Srinivas S. Somanchi Breakdown of academic impact, for papers by Dina Stroopinsky Breakdown of academic impact, for papers by Felix S. Lichtenegger Breakdown of academic impact, for papers by Mobin Karimi Breakdown of academic impact, for papers by Britt E. Anderson Breakdown of academic impact, for papers by May Daher
Rankless by CCL
2026